New York city, USA, May 5th, 2026, FinanceWirePTC Therapeutics entered 2026 focused on a regulatory milestone that ...

10 min read | PTC Therapeutics shared 2-year data for votoplam, a daily HTT-lowering pill. Stage 2 participants showed up to ...

The boost comes after the U.S. Food and Drug Administration indicated in March that its trial data are not sufficient to support approval. ・The company will meet with the FDA in Q2 to discuss a ...

Huntington’s disease (HD) is a devastating brain disorder that slowly robs people of movement, memory and personality. It is caused by a toxic, mutant Huntingtin (mHTT) protein that builds in brain ...

Treatments that target a fragment of the mutant protein that causes Huntington's disease might be more effective than treatments, now in clinical trials, that target the whole protein but leave this ...

Researchers have elucidated key steps in the ubiquitin tagging of the mutated huntingtin protein, providing hope for future therapies. There is no known cure for Huntington's disease. A genetic ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. New gene therapies such as AMT‑130 are beginning to slow Huntington’s disease progression, ...

Huntington’s disease (HD) has long been impossible to cure, but new research is finally giving fresh hope. HD is a progressive, hereditary brain disease that affects movement, cognition and emotions.

Huntington’s disease (HD) has long been impossible to cure, but new research is finally giving fresh hope. HD is a progressive, hereditary brain disease that affects movement, cognition and emotions.

Caused by a CAG repeat in the first exon of the huntingtin (HTT) gene, Huntington’s is a genetic, neurodegenerative disease that strikes patients during the prime of their lives—typically in their 30s ...